Amiodarone (AM), a drug used in the treatment of cardiac dysrrhythmias, can produce
severe pulmonary adverse effects, including fibrosis. Although the pathogenesis of AM …

Amiodarone (AM), a potent antidysrhythmic agent, can cause potentially life-threatening
pulmonary fibrosis. In the present investigation of mechanisms of initiation of AM lung …

Amiodarone (AM) is a potent antidysrhythmic agent that can cause potentially life-
threatening pulmonary fibrosis, and N-desethylamiodarone (DEA), an AM metabolite, may …

Amiodarone (AM) is an effective antidysrhythmic agent, restricted in use by the development
of adverse effects, including potentially fatal AM‐induced pulmonary toxicity (AIPT). Although …

Amiodarone (AM) is an efficacious antidysrhythmic agent that is limited clinically by
numerous adverse effects. Of greatest concern is AM-induced pulmonary toxicity (AIPT) due …

Amiodarone (AD) is gaining support as a first-line antiarrhythmic drug despite its potentially
fatal pulmonary toxicity involving inflammation and fibrosis. We previously reported a model …

The effectiveness of amiodarone in the treatment of cardiac arrhythmias is limited due to the
development of pulmonary toxicity. Although the biochemical and morphologic …

Amiodarone (AM), an antidysrrhythmic drug, can produce serious adverse effects, including
potentially fatal AM-induced pulmonary toxicity (AIPT). AM-induced cytotoxicity and …

Background: The clinical usefulness of amiodarone for the treatment of cardiac arrhythmias
is limited by multiorgan toxicity, especially pulmonary and hepatic. There are conflicting …

Associated with amiodarone (AM) therapy is pneumonitis, which may progress to life-
threatening pulmonary fibrosis. Although the etiology of amiodarone-induced pulmonary …